Akebia Therapeutics

Akebia CEO John Butler
Pharma

Akebia drops Vafseo trial, failing to get 'alignment' with FDA

Akebia has scrapped plans for a trial that would have potentially led to an expansion of the patient population for its new anemia drug Vafseo.
Kevin Dunleavy Oct 29, 2025 11:31am
expansion milestones advance advancing progress

Akebia sketches out pivotal Vafseo study in nondialysis patients

Mar 13, 2025 3:28pm
chronic kidney disease money

Akebia unveils IRA-driven high price for Vafseo

Jul 11, 2024 10:54am
Photo of a person celebrating at the top of the mountain while the sun setsrises

Akebia's Vafseo wins FDA approval 2 years after rejection

Mar 28, 2024 9:25am
Patient monitored by electronic sphygmomanometer during dialysis session Advanced dialysis equipment in hospital

After high-profile snub, Akebia plots vadadustat resubmission

Aug 24, 2023 10:40am
stop shut down close end button

GSK scraps plan to launch oral anemia drug beyond US, Japan

Jul 26, 2023 10:21am